MedTrace Logo

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)

NCT02788877 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-03-01

No results posted yet for this study

Summary

Efficacy of Treat-and-extend regimen (TER) using aflibercept in diabetic macular edema (DME) will be evaluated.

Conditions

  • Macular Edema, Diabetic

Interventions

DRUG

aflibercept

Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Jae Pil Shin, MD, PhD · Kyungbuk National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-10
Primary Completion
2019-09-30
Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02788877 on ClinicalTrials.gov